The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicogenomic analysis of EGFR-mutant lung cancers for identification of Rb inactivation as a hallmark of squamous transformation.
 
Mark Jeng
No Relationships to Disclose
 
Alexandria Dymun
No Relationships to Disclose
 
Allison Richards
No Relationships to Disclose
 
Mark Donoghue
Employment - Lilly (I)
Stock and Other Ownership Interests - Lilly (I)
Research Funding - Loxo
 
Arielle Elkrief
Honoraria - Astrazeneca; Bristol-Myers Squibb; EMD Serono; Merck
Consulting or Advisory Role - Bristol Myers Squibb
Research Funding - AstraZeneca (Inst); Kanvas Bioscience (Inst); Merck (Inst)
Other Relationship - Canadian Institutes of Health Research (CIHR); Cedars Cancer Center; Royal College of Surgeons and Physicians of Canada
 
Helena Yu
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Bristol-Myers Squibb/Roche; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen; Novocure; Orion Clinical; Taiho Oncology; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Systimmune (Inst)
Other Relationship - Astellas Pharma
 
Alvaro Quintanal-Villalonga
Honoraria - AstraZeneca
Research Funding - Duality Biologics; Foghorn Therapeutics; Jazz Pharmaceuticals